Pemigatinib is an FGFR inhibitor. It’s specifically made to treat cholangiocarcinoma when there’s an FGFR2 fusion. You’ve got three strengths to choose from: 4.5 mg, 9 mg, and 13.5 mg tablets.
The usual dose is 13.5 mg a day, for 14 days straight, over a 21-day cycle. So, each cycle is two 14-day on periods and then a 7-day break. Each bottle has 14 tablets, enough for a full 21-day cycle.
